Imviva Biotech is cleared to launch a basket Phase 1b trial testing its investigational off-the-shelf CAR T-cell therapy CTA313 in progressive multiple sclerosis (MS) and other B-cell-mediated autoimmune diseases. The announcement follows the clearance of the company’s investigational new drug (IND) application by the U.S. Food and Drug…
Discussion
Among people with clinically isolated syndrome (CIS) — an initial episode of symptoms suggestive of multiple sclerosis (MS) — lower levels of certain fatty molecules in the blood are associated with higher rates of future disease relapses, a new study found. Adding these metabolic features to established demographic…
Discussion
Many people tend to associate post-traumatic stress disorder (PTSD) with military service. While the military may provide ample opportunities for exposure to a traumatic event, it by no means has a monopoly on the disorder. Trauma can be caused by many other situations, including terrifying or stressful medical experiences. Examples…
Discussion
A new study in mice shows that an advanced imaging technique called magnetic particle imaging, or MPI, can track exactly where therapeutic cells go after they are injected into the body. This approach could eventually help researchers and doctors study and optimize cell-based therapies for people with multiple sclerosis…
Discussion
The approved injection therapy Kesimpta (ofatumumab) is generally safe and helps most adults with relapsing forms of multiple sclerosis (MS) keep their disease stable over time with few or no relapses, a real-world study has found. The data show treatment is especially effective when started at a younger…
Get regular updates to your inbox.
